Ganciclovir
- Generic Name
- Ganciclovir
- Brand Names
- Cytovene, Zirgan
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N5O4
- CAS Number
- 82410-32-0
- Unique Ingredient Identifier
- P9G3CKZ4P5
- Background
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
- Indication
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised pat...
- Associated Conditions
- CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- -
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002273
- Locations
- 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States
A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00002257
- Locations
- 🇨🇦
Saint Paul's Hosp, Vancouver, British Columbia, Canada
🇺🇸New York Univ Med Ctr, New York, New York, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Roche Global Development
- Target Recruit Count
- 280
- Registration Number
- NCT00002330
- Locations
- 🇺🇸
Dr Ken Fisher, Phoenix, Arizona, United States
🇺🇸Dr Daniel Barbero, Fort Worth, Texas, United States
🇺🇸Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002025
- Locations
- 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00002096
- Locations
- 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Ctr for Special Immunology, Irvine, California, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Roche Global Development
- Target Recruit Count
- 450
- Registration Number
- NCT00002134
- Locations
- 🇺🇸
Saint Clare's Prof Office, New York, New York, United States
🇺🇸Dr Neil Brourman, Beverly Hills, California, United States
🇺🇸Santa Clara Valley Med Ctr, San Jose, California, United States
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 130
- Registration Number
- NCT00001100
- Locations
- 🇺🇸
NIAID/DMID/CASG Central Unit, Birmingham, Alabama, United States
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 180
- Registration Number
- NCT00000688
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Stanford Univ School of Medicine, Stanford, California, United States
🇺🇸Kansas City Veterans Administration Med Ctr, Kansas City, Missouri, United States
CMV Retinitis Retreatment Trial
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 300
- Registration Number
- NCT00000766
- Locations
- 🇺🇸
Johns Hopkins Hosp / SOCA, Baltimore, Maryland, United States
🇺🇸New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA, New York, New York, United States
🇺🇸Mount Sinai Med Ctr / SOCA, New York, New York, United States
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-02-23
- Target Recruit Count
- 300
- Registration Number
- NCT00000894
- Locations
- 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸New York Hosp / Cornell Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.